Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 447 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 447 shares of the firm’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $90.22, for a total transaction of $40,328.34. Following the sale, the insider now directly owns 347,731 shares in the company, valued at approximately $31,372,290.82. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Jonathan Sheena also recently made the following trade(s):

• On Tuesday, March 5th, Jonathan Sheena sold 1,028 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $90,834.08.
• On Tuesday, February 6th, Jonathan Sheena sold 6,000 shares of Natera stock. The stock was sold at an average price of $70.00, for a total transaction of $420,000.00.
• On Monday, January 22nd, Jonathan Sheena sold 351 shares of Natera stock. The stock was sold at an average price of $68.16, for a total transaction of $23,924.16.
• On Wednesday, January 3rd, Jonathan Sheena sold 5,000 shares of Natera stock. The stock was sold at an average price of $60.30, for a total transaction of $301,500.00.

Natera Price Performance

NTRA traded up $1.00 during trading hours on Friday, hitting $91.46. The company’s stock had a trading volume of 971,264 shares, compared to its average volume of 1,783,625. The business’s 50-day moving average price is $78.46 and its 200-day moving average price is $61.25. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $96.24. The stock has a market cap of $11.04 billion, a price-to-earnings ratio of -24.13 and a beta of 1.39. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.09. The company had revenue of $311.11 million for the quarter, compared to analysts’ expectations of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. Sell-side analysts expect that Natera, Inc. will post -2.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, March 14th. Stephens restated an “overweight” rating and set a $78.00 target price on shares of Natera in a research note on Tuesday, January 30th. Guggenheim started coverage on shares of Natera in a research note on Thursday, December 14th. They set a “buy” rating and a $70.00 target price on the stock. Piper Sandler raised their target price on shares of Natera from $70.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. Finally, Canaccord Genuity Group raised their target price on shares of Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and an average price target of $78.36.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. RiverPark Advisors LLC purchased a new position in Natera during the fourth quarter worth $27,000. Principal Securities Inc. purchased a new stake in shares of Natera during the fourth quarter valued at $32,000. Kayne Anderson Rudnick Investment Management LLC purchased a new stake in shares of Natera during the second quarter valued at $29,000. Pinebridge Investments L.P. purchased a new stake in shares of Natera during the second quarter valued at $33,000. Finally, Oliver Lagore Vanvalin Investment Group boosted its stake in shares of Natera by 109.3% during the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 389 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.